Insurers, pension funds, and Restasis users accusing Allergan of conspiring to delay generic competition for the dry eye drug convinced a Brooklyn federal judge to grant them class action status, reported Bloomberg.
Although the class of “end payer plaintiffs” likely contains some “brand loyalists” who weren’t harmed by the company’s alleged sham litigation scheme, the plaintiffs’ expert adequately demonstrated that the number was “de minimis,” Judge Nina Gershon wrote Tuesday, May 5.
The ruling comes about 10 weeks after Allergan agreed to settle parallel claims by drug distributors for US$51 million.
The sprawling antitrust suit accuses Allergan of “inundating” the Food and Drug Administration (FDA) with bad faith “citizen petitions” challenging the safety of Restasis generics proposed by other drugmakers. After the FDA rejected the petitions, Allergan allegedly launched bogus lawsuits claiming its would-be competitors infringed patents it had intentionally mischaracterized to regulators.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Urged to Enforce Rarely Used Antitrust Law Against Retail Giants
Mar 28, 2024 by
CPI
UK’s Fingleton Bolsters Team with New Additions
Mar 28, 2024 by
CPI
Britain’s Competition Regulator Clears Aviva’s Acquisition of AIG Life UK
Mar 28, 2024 by
CPI
White House Implements New AI Safeguards to Protect Rights and Safety
Mar 28, 2024 by
CPI
Denver Court Sets August Date for Kroger-Albertsons Merger Showdown
Mar 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Real Estate & Antitrust
Mar 27, 2024 by
CPI
Systematic National Evidence of Steering by Real Estate Agents
Mar 27, 2024 by
CPI
Compliance Now! Actionable Antitrust Advice for the Residential Real Estate Industry
Mar 27, 2024 by
CPI
Real Estate Commissions: Some Insights from the Economics of Multi-Sided Platforms
Mar 27, 2024 by
CPI
New Ideas for Promoting Real Estate Brokerage Price Competition
Mar 27, 2024 by
CPI